TG4050 is an individualized immunotherapy being developed for solid tumours that is based on Transgene’s myvac platform and powered by NEC’s cutting-edge AI capabilities designed to optimize antigen ...
Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight ...
Selection of 19 individual researchers among ... Cheever and colleagues establish a definition of 'ideal' antitumor vaccine antigens based on weighted criteria, including: evidence of antitumor ...
Several observations point toward the possibility of a vaccine development strategy ... of most of these surface proteins has made antigen selection problematic. Obstacles to the development ...
Immune responses targeting selected neoantigens were identified in 100% of patients who received TG4050, demonstrating the strong immunogenicity of the cancer vaccine, with both de novo and ...
Here, Jeffrey Almond discusses the selection of articles in this Focus ... Their ultimate goal is epitope engineering of important vaccine antigens, although the feasibility of this for large ...
While RNA vaccines are being evaluated in clinical trials, current practice of antigen selection is based on the predicted stability of antigens on the surface of tumor cells. "It's not so black ...
Existing vaccines have been developed mostly against ... by several orders of magnitude and making possible the selection of antigens that are conserved and that induce antibody-mediated protection.